Trials of the controversial anti-malarial drug taken by US President Donald Trump to try to prevent catching coronavirus are to be resumed.

UK regulators say hydroxychloroquine and a similar drug chloroquine can be given to healthcare workers in a clinical study to test the theory.

Recruitment to the COPCOV trial had been paused amid concerns about side-effects raised by other research that has since been discredited.

That work looked at treating Covid-19.

It concluded the drug was not beneficial and increased the risk of irregular heart rhythms and death. That publication led to the WHO suspending its coronavirus treatment trials of the anti-malaria drug.

Concerns were raised about the data and then some of the study’s authors said they could no longer stand by their publication in

Read More At Article Source | Article Attribution